References
- Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., & He, J. X. (2019). & Zhong, NS (2020). Clinical characteristics of coronavirus disease, 1708–1720.
- Wu, Y., Ho, W., Huang, Y., Jin, D. Y., Li, S., Liu, S. L., ... & Zheng, Z. M. (2020). SARS-CoV-2 is an appropriate name for the new coronavirus. The Lancet, 395(10228), 949–950.
- Cucinotta, D., & Vanelli, M. (2020). WHO declares COVID-19 a pandemic. Acta bio medica: Atenei parmensis, 91(1), 157.
- Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., ... & Tan, W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine.
- Bedford, J., Enria, D., Giesecke, J., Heymann, D. L., Ihekweazu, C., Kobinger, G., ... & Wieler, L. H. (2020). WHO Strategic and Technical Advisory Group for Infectious Hazards. COVID-19: towards controlling of a pandemic. Lancet, 395(10229), 1015–1018.
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497–506.
- Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet, 395(10229), 1033–1034.
- Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. (2020). The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology, 20(6), 363–374.
- Berlin, D. A., Gulick, R. M., & Martinez, F. J. (2020). Severe COVID-19. New England Journal of Medicine, 383(25), 2451–2460.
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., ... & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 395(10229), 1054–1062.
- Tobin, M. J., Laghi, F., & Jubran, A. (2020). Why COVID-19 silent hypoxemia is baffling to physicians. American journal of respiratory and critical care medicine, 202(3), 356–360.
- Liu, Y., Lv, J., Liu, J., Li, M., Xie, J., Lv, Q., ... & Huang, B. (2020). Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19. Cell Research, 30(12), 1078–1087.
- Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama, 323(18), 1824–1836.
- Almazroo, O. A., Miah, M. K., & Venkataramanan, R. (2017). Drug metabolism in the liver. Clinics in liver disease, 21(1), 1–20.
- Wang, K., Zuo, P., Liu, Y., Zhang, M., Zhao, X., Xie, S., ... & Liu, C. (2020). Clinical and laboratory predictors of in-hospital mortality in patients with coronavirus disease-2019: a cohort study in Wuhan, China. Clinical infectious diseases, 71(16), 2079–2088.
- Ramos-Lopez, O., Daimiel, L., Ramírez de Molina, A., Martínez-Urbistondo, D., Vargas, J. A., & Martínez, J. A. (2020). Exploring host genetic polymorphisms involved in SARS-CoV infection outcomes: Implications for personalized medicine in COVID-19. International journal of genomics, 2020.
- Keyvani, H., Zahednasab, H., Sholeh, M., Mirzaei, R., Esghaei, M., & Karampoor, S. (2020). Gender Preponderance Might be Associated with the Severity of COVID-19 Infection. J Clin Cell Immunol, 11, 598.
- Karampoor, S., Afrashteh, F., & Laali, A. (2021). Persistent hiccups after treatment of COVID-19 with dexamethasone: A case report. Respiratory Medicine Case Reports, 34, 101515.
- Hill, A. V. (2012). Evolution, revolution and heresy in the genetics of infectious disease susceptibility. Philosophical Transactions of the Royal Society B: Biological Sciences, 367(1590), 840–849.
- Patarčić, I., Gelemanović, A., Kirin, M., Kolčić, I., Theodoratou, E., Baillie, K. J., ... & Polašek, O. (2015). The role of host genetic factors in respiratory tract infectious diseases: systematic review, meta-analyses and field synopsis. Scientific reports, 5(1), 16119.
- Yucesoy, B., Kapici, S., Sercan, C., Yigitbasi, T., Emekli, N., & Ulucan, K. (2017). Determination of the Distribution of the rs2069514 and rs762551 Alleles of the Cyp1a2 Gene Related to Caffeine Metabolism in Professional Athletes. European Journal of Biology, 76(2), 69–73.
- Pijls, B. G., Jolani, S., Atherley, A., Dijkstra, J. I., Franssen, G. H., Hendriks, S., ... & Zeegers, M. P. (2022). Temporal trends of sex differences for COVID-19 infection, hospitalisation, severe disease, intensive care unit (ICU) admission and death: a meta-analysis of 229 studies covering over 10M patients. F1000Research, 11.
- Cohen, J. F., Korevaar, D. A., Matczak, S., Chalumeau, M., Allali, S., & Toubiana, J. (2021). COVID-19–related fatalities and intensive-care-unit admissions by age groups in Europe: a meta-analysis. Frontiers in Medicine, 7, 560685.
- Teker, A. G., Emecen, A. N., Girgin, S., Şimşek-Keskin, H., Şiyve, N., Sezgin, E., ... & Ünal, B. (2021). Türkiye’de Bir Üniversite Hastanesinde COVID-19 Olgularının Epidemiyolojik Özellikleri. Klimik Journal/Klimik Dergisi, 34(1).
- Jain, V., & Yuan, J. M. (2020). Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. International journal of public health, 65, 533–546.
- Yamamoto, N., Ariumi, Y., Nishida, N., Yamamoto, R., Bauer, G., Gojobori, T., ... & Mizokami, M. (2020). SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype. Gene, 758, 144944.
- Gómez, J., Albaiceta, G. M., García-Clemente, M., López-Larrea, C., Amado-Rodríguez, L., Lopez-Alonso, I., ... & Coto, E. (2020). Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene, 762, 145102.
- Pinheiro, D. S., Santos, R. S., Jardim, P. C. V., Silva, E. G., Reis, A. A., Pedrino, G. R., & Ulhoa, C. J. (2019). The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients. PloS one, 14(8), e0221248.
- Lenoir, C., Terrier, J., Gloor, Y., Curtin, F., Rollason, V., Desmeules, J. A., ... & Samer, C. F. (2021). Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva cocktail. Clinical Pharmacology & Therapeutics, 110(5), 1358–1367.
- Kar, N., Barreto, S., & Chandavarkar, R. (2016). Clozapine monitoring in clinical practice: beyond the mandatory requirement. Clinical Psychopharmacology and Neuroscience, 14(4), 323.
- de Leon, J. (2004). Respiratory infections rather than antibiotics may increase clozapine levels: a critical review of the literature. The Journal of clinical psychiatry, 65(8), 18148.
- Dotson, S., Hartvigsen, N., Wesner, T., Carbary, T. J., Fricchione, G., & Freudenreich, O. (2020). Clozapine toxicity in the setting of COVID-19. Psychosomatics, 61(5), 577.
- DiAngelo, Z., Berlin, J., Wang, S., Gutowski, B., & Bahnsen, R. (2022). (32) Clozapine Toxicity Following COVID-19 Infection: A Case Series. Journal of the Academy of Consultation-liaison Psychiatry, 63, S128–S128.
- Reis, G., dos Santos Moreira-Silva, E. A., Silva, D. C. M., Thabane, L., Milagres, A. C., Ferreira, T. S., ... & Mills, E. J. (2022). Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. The Lancet Global Health, 10(1), e42–e51.
- Tio, N., Schulte, P. F., & Martens, H. J. (2021). Clozapine intoxication in COVID-19. American Journal of Psychiatry, 178(2), 123–127.
- Elfaki, I. (2022). The Impact of the Coronavirus (COVID-19) Infection on the Drug-Metabolizing Enzymes Cytochrome P450s. Drug Metabolism and Bioanalysis Letters Formerly: Drug Metabolism Letters, 15(2), 71–74.
- Thorn, C. F., Aklillu, E., Klein, T. E., & Altman, R. B. (2012). PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenetics and genomics, 22(1), 73.
- Rahman, M. S., & Thomas, P. (2018). Interactive effects of hypoxia and PCB co-exposure on expression of CYP1A and its potential regulators in Atlantic croaker liver. Environmental toxicology, 33(4), 411–421.